Indeed, the successive discovery of the gain-of-function V617F mutation in JAK2 in 2005 [8] and the JAK2 exon 12 mutation in 2007 [9], respectively, allowed a major advance in molecular characterization of these BCR::ABL1-negative MPN. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.